1300 ESTIMATING THE BURDEN OF PREOPERATIVELY MISCLASSIFIED, SURGICALLY REMOVED BENIGN RENAL MASSES IN THE UNITED STATES: IMPLICATIONS FOR THE CURRENT STANDARD OF CARE

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
David Johnson ◽  
Angela Smith ◽  
Josip Vukina ◽  
Jed Ferguson ◽  
Will Kirby ◽  
...  
Keyword(s):  
United States ◽  
Standard Of Care ◽  
The United States ◽  
Current Standard ◽  
Renal Masses

Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs

2021 ◽  
Vol 42 (3) ◽  
pp. S17-S25 ◽  
Author(s):  
Marc A. Riedl ◽  
Timothy J. Craig ◽  
Aleena Banerji ◽  
Kavita Aggarwal ◽  
Jessica M. Best ◽  
...  
Keyword(s):  
United States ◽  
Hereditary Angioedema ◽  
Standard Of Care ◽  
The United States ◽  
The Body ◽  
Current Standard ◽  
Prescribing Trends ◽  
Individualized Approach ◽  
The Impact

Hereditary angioedema (HAE) is a rare disorder caused by genetic mutations that lead to recurrent episodes of swelling in various parts of the body. Prophylactic treatment is common for patients with HAE, and the therapeutic options have expanded in recent years. The current standard of care for prophylactic HAE therapies is subcutaneous treatment, which can be self-administered at home, greatly improving patient quality of life. As new therapies emerge, it is important for patients and physicians to discuss the risks and benefits associated with each treatment to develop an individualized approach to HAE management. We conducted surveys of patients with HAE and physicians who treat patients with HAE to identify prescribing trends for prophylactic HAE treatments and the impact that such treatments has on patients. Our results confirmed that newer, subcutaneous therapies are prescribed for HAE prophylaxis more frequently than other therapies in the United States and that treatment burdens still exist for patients with HAE. We found that physicians and patients were not always aligned on how treatment choices affect patients’ lives, which may mean that there are opportunities for enhanced patient‐physician dialog and shared decision-making in HAE management in the United States.

Abdominal Pain

2018 ◽  
pp. 327-331
Author(s):  
Elizabeth DeVos
Keyword(s):  
United States ◽  
Signs And Symptoms ◽  
Standard Of Care ◽  
Clinical Decision ◽  
Operative Management ◽  
The United States ◽  
Potential Utility ◽  
Treatment Protocols ◽  
Common Presentation ◽  
Treatment Risks

This case demonstrates a common presentation of appendicitis including frequent signs and symptoms and classic examination findings. Options for diagnostic imaging are reviewed. Clinical decision scores may assist in risk stratification, which may be particularly useful in austere or low-resource settings. The discussion introduces the concept of “antibiotics first” treatment for appendicitis including a discussion of patients who are poor candidates for such treatment, risks for need of future operative management, and proposed treatment protocols. While surgical management remains the standard of care in the United States, this case discusses potential utility for an “antibiotics first” protocol when definitive surgical treatment is not readily available.

scholarly journals Regulation and Practice of Forest-Management Fires on Private Lands in the Southeast United States: Legal Open Burns versus Certified Prescribed Burns

2020 ◽  
Vol 118 (4) ◽  
pp. 385-402
Author(s):  
Xue Han ◽  
Gregory E Frey ◽  
Changyou Sun
Keyword(s):  
United States ◽  
Forest Management ◽  
Standard Of Care ◽  
Past Research ◽  
The United States ◽  
Management Tool ◽  
Policy And Practice ◽  
Private Lands ◽  
Prescribed Burns ◽  
Southeast United States

Abstract Abstract Forest-management burns have been widely acknowledged as a useful land-management tool in the United States. Nevertheless, fire is inherently risky and may lead to severe damages or create smoke that affects public health. Past research has not explored the difference in policy and practice between open burns, which meet minimum legal criteria, and certified prescribed burns, which follow a higher standard of care. This study seeks to understand the distinction between legal open burns and certified prescribed burns, and, furthermore, to identify trends by type of burn in the Southeast United States. To that end, we compared statutes, regulations, incentives, and notifications of fire as a forest-management tool among nine states in the US Southeast. We found no steady time trends in number or area of burns among the states for the past decade. A nontrivial proportion of legal open burns, which tend to be smaller burns, are noncertified burns, meaning they meet minimum legal requirements, but not the higher standard required for certified prescribed burns.

scholarly journals Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States

2019 ◽  
Vol 36 (7) ◽  
pp. 1715-1729 ◽  
Author(s):  
Stacey Kowal ◽  
Eliza Kruger ◽  
Pinar Bilir ◽  
James H. Holmes ◽  
William Hickerson ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Standard Of Care ◽  
The United States ◽  
Severe Burns ◽  
Autologous Cell ◽  
Cell Harvesting

A decision-analytic model of idelalisib in relapsed or refractory patients with follicular lymphoma in the United States.

2014 ◽  
Vol 32 (30_suppl) ◽  
pp. 30-30 ◽  
Author(s):  
Nathaniel Smith ◽  
Alexander Xenakis ◽  
Rachel Beckerman ◽  
Jagpreet Chhatwal ◽  
Stephanie A. Gregory ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Follicular Lymphoma ◽  
Survival Data ◽  
Treatment Options ◽  
Standard Of Care ◽  
The United States ◽  
Sensitivity Analyses ◽  
Decision Analytic Model ◽  
Current Standard ◽  
Utilization Data

30 Background: There are currently few treatment options for relapsed/refractory (RR) indolent non-Hodgkin’s lymphoma (iNHL) patients. Idelalisib (IDELA) is a first-in class PI3Kδ inhibitor with substantial clinical efficacy in iNHL patients refractory to rituximab and an alkylating agent. A single-arm clinical trial (Study 101-09) showed RR iNHL patients treated with IDELA have a median of 11 and 20.3 months of progression-free and overall survival (PFS and OS), respectively. Efficacy was also demonstrated in patients with iNHL subtypes such as follicular lymphoma (FL). The objective of this study was to project the health outcomes of IDELA versus the current standard of care for US FL patients. Methods: A partitioned survival model simulated a cohort of RR FL patients over 10 year time horizon. Patients first received IDELA or an aggregate comparator of current RR iNHL chemotherapy regimens in a progression-free state before transitioning to a progressive-disease state where they received palliative care until death. Survival data was fit and extrapolated from Study 101-09 (IDELA) for FL patients. A real-world database claims analysis provided survival, disease- and treatment-related adverse event (AEs) profiles, and medical resource utilization data for RR iNHL patients for the comparator. All outcomes were discounted at 3%. Results: Claims data predicted a median of 6.16 and 13.04 months of PFS and OS, respectively, for the comparator. Our model suggests that IDELA treatment improved health outcomes over 10 years versus the comparator, increasing life-months (LMs) and progression-free life-months (PFLMs) by 9.94 and 4.63 mos, respectively. Over 1 year, IDELA reduced both AEs and hospitalisations in FL patients by 40.3% and 49.8%, respectively. Deterministic and probabilistic sensitivity analyses demonstrated the model results are robust across different methods of survival extrapolation. Conclusions: IDELA was projected to improve health outcomes in RR FL patients compared to current treatments, largely driven by improved PFS and OS; short-term reductions in AEs and hospitalisation were specifically related to a delayed disease progression.

Sign in / Sign up

Export Citation Format

Share Document